Valuation: Genelux Corporation

Market Cap 115M 99.73M 93.83M 85.28M 160M 11.06B 163M 1.1B 431M 5.53B 434M 424M 18.43B P/E 2026 *
-3.16x
P/E 2027 * -3.46x
Enterprise Value 115M 99.73M 93.83M 85.28M 160M 11.06B 163M 1.1B 431M 5.53B 434M 424M 18.43B EV / Sales 2026 *
-
EV / Sales 2027 * 7.9x
Free-Float
86.18%
Yield 2026 *
-
Yield 2027 * -
1 day-3.70%
1 week-1.89%
Current month-11.56%
1 month-9.41%
3 months-8.77%
6 months-0.76%
Current year-40.37%
1 week 2.56
Extreme 2.555
2.82
1 month 2.5
Extreme 2.5
3.08
Current year 2.29
Extreme 2.29
4.99
1 year 2.29
Extreme 2.29
8.54
3 years 1.6
Extreme 1.6
30.44
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 28/05/2014
Director of Finance/CFO 42 30/01/2025
Chief Tech/Sci/R&D Officer 52 02/01/2026
Director TitleAgeSince
Director/Board Member 68 01/09/2002
Chairman 73 01/01/2014
Chairman 67 01/04/2023
Date Insider Type Main position Quantity % Market Cap.
8/4/26 A Sell

Chief Technology Officer

-653 0.0015%
8/4/26 A Sell

Chief Technology Officer

-653 0.0015%
8/4/26 A Sell

Chief Executive Officer

-3,023 0.0067%
Change 5-day change 1-year change 3-year change Capi.($)
-3.70%-1.89%-26.55%-89.16% 115M
+0.17%+4.35%+72.39%+114.97% 73.45B
+1.73%+16.15%+51.73%+93.89% 62.99B
+0.11%-3.10%+0.94%+491.16% 28.05B
-1.48%+4.68%+60.64%+20.20% 25.42B
+1.26%-0.05%-17.59%-15.96% 23.3B
0.00%+5.57%+39.57%-14.30% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.59%-1.23%+14.47%+514.12% 16.53B
+1.53%+3.49%+40.68%+151.75% 13.16B
Average -0.49%+2.15%+48.03%+169.05% 28.06B
Weighted average by Cap. +0.21%+4.96%+55.97%+164.57%

Financials

2026 *2027 *
Net sales - 14.62M 12.63M 11.88M 10.8M 20.31M 1.4B 20.6M 139M 54.61M 701M 54.88M 53.69M 2.33B
Net income -37.46M -32.35M -30.44M -27.67M -52.04M -3.59B -52.8M -357M -140M -1.8B -141M -138M -5.98B -38.31M -33.09M -31.13M -28.29M -53.22M -3.67B -54M -365M -143M -1.84B -144M -141M -6.11B
Net Debt - -
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
18/08/26 $2.600 -3.70% 379,006
17/08/26 $2.700 -1.46% 265,149
14/08/26 $2.740 +4.18% 462,788
13/08/26 $2.630 -2.59% 315,709
12/08/26 $2.700 +1.89% 250,836
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.600USD
Average target price
17.50USD
Spread / Average Target
+573.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNLX Stock